4th Annual
Obesity & Weight Loss
Drug Development Summit

RenBio®

Ultra long-lasting, DNA-Based Delivery of Incretin Receptor Agonists

July 16, 2026

Rachel Liberatore, PhD
President and CSO

Linda Sasset, PhD

Forward-looking statements

No representation, express or implied, is being given by RenBio, Inc. or its affiliates (individually and collectively, the "Company") as to the accuracy or completeness of the information contained herein. The Company expressly disclaims any and all liability (whether known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, due or become due, or otherwise) or any indemnification or other obligation which may be based on this presentation, errors therein or omissions therefrom.

This presentation is not and shall not be construed or viewed in any way to be a commitment, offer, obligation or agreement with respect to any transaction with the Company.

This presentation may contain "forward-looking" statements, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, should be deemed forward-looking statements, and reflect the current expectations and assumptions about future events and are not guarantees of future performance. Actual results could differ materially from the current expectations because of many factors. All forward-looking statements herein reflect opinions only as of the date of this presentation.

RenBio

MYO Technology

Paradigm shift in delivery of antibodies and therapeutic proteins
for treatment of chronic diseases and prevention of infectious diseases

RenBio

MYO® TECHNOLOGY

Bio Blueprints

Proprietary DNA plasmid

Delivery Device

Proprietary electroporation device

Antibody Factory

Muscle cells produce proteins following in vivo transfection

Antibodies/Therapeutic Proteins

Circulate systemically following secretion

RenBio

MYO Technology Delivery Device

Generator

Handpiece



RenBio

MYO Technology enables ultra durable protein expression

Traditional antibody protein delivery



MYO delivery of antibody genes



Unpublished, internal data

RenBio

MYO Technology is a perfect fit for chronic disease treatment and infectious disease prevention

Feature	MYO Technology	mRNA	AAV Gene Therapy
Durability	**Months to years**	Weeks to months	Years/Permanent
Redosable	****	***	*
Large genetic payload	****	***	**
Large scale manufacturing	****	**	*
Freedom from cold chain	****	*	*
Clinical safety of technology	***	***	*
Opportunity	Systemic activity Chronic disease Tx Infectious disease Px	Localized activity Short half-life Vaccines	Specific tissue target Genetic disease Tx

Pipeline: mAbs and therapeutic proteins



RenBio

Delivery of an anti-Zika virus mAb with MYO Technology protects rhesus macaques in a Zika challenge model

Animals treated with MYO Technology had ~10,000-fold reduction in peak viral loads

Plasma viral loads

Sham



Zika mAb



Peak plasma viral loads



RenBio

Unpublished, internal data

J. Crowe, VUMC
D. Barouch, BIDMC
DARPA

Preclinical PoC for G-CSF and anti-IL-23 delivery with MYO Technology

MYO anti-IL-23: DNA-based delivery of guselkumab potently inhibits IL-23-induced psoriasis



Unpublished, internal data

MYO G-CSF: DNA dose-dependent treatment of anti-Ly6G-induced neutropenia



Drozdz MM, et al. Molecular Therapy (2025), https://doi.org/10.1016/j.ymthe.2025.03.038

RenBio

MYO Technology

features

RenBio

In vivo electroporation efficiently transfects muscle cells within the footprint of the device



RenBio

Protein expression correlates with the amount of pDNA



RenBio

MYO Technology permits robust repeated dosing



RenBio

MYO Technology permits simultaneous delivery of multiple molecules at the same site



RenBio

MYO Technology permits delivery of multiple molecules at different sites

Sequential delivery



Co-delivery



RenBio

MYO Technology

Preclinical results on Incretin Receptor Agonists

RenBio

DNA-based delivery of GLP-1 peptide is efficacious in a DIO model



Weight Loss



Food Intake



Glucose clearance



RenBio

GLP-1 fused to an Fc domain exhibits therapeutic effects comparable to those of semaglutide







RenBio

GLP-1 fused to an Fc domain exhibits therapeutic effects comparable to those of semaglutide

Weight Loss



Food Intake



Glucose clearance



CTRL GLP-1-mIgG1(Fc) Semaglutide

RenBio

DNA-based delivery of GLP-1 Fc fusion improves therapeutic effects compared to native GLP-1



Weight Loss



Serum level



Food Intake



RenBio

DNA-based delivery of GLP-1 Fc fusion improves therapeutic effects compared to native GLP-1





RenBio

Will enhanced BBB penetration further improve efficacy?





RenBio

Enhanced BBB targeting dramatically improves GLP-1 Fc fusion efficacy







RenBio

Sasset et al., Molecular Therapy Nucleic Acids.
DOI: 10.1016/j.omtn.2026.102946

Enhanced BBB targeting dramatically improves GLP-1 Fc fusion efficacy



Food Intake



Serum level



RenBio

Enhanced BBB targeting dramatically improves GLP-1 Fc fusion efficacy



Glucose clearance



RenBio

Enhanced BBB targeting dramatically improves GLP-1 Fc fusion efficacy



Weight loss



Serum level



RenBio

Enhanced BBB targeting dramatically improves GLP-1 Fc fusion efficacy



Glucose clearance



RenBio

Human Fc fusion is also efficacious in a DIO model





RenBio

Human Fc fusion is also efficacious in a DIO model



Weight Loss



Food Intake



Serum level



CTRL GLP-1-hIgG4(Fc)-Angp2

RenBio

Human Fc fusion demonstrates similar effects in a DIO model





RenBio

Angiopep-2 enhances BBB penetration of GLP-1 Fc fusion





RenBio



RenBio

DNA-Encoded Incretin Receptor Agonists

- Durability:
  - Ultra long-term production of IRA and efficacy
- Flexibility:
  - Simultaneous or sequential delivery of multiple molecules
- Scale:
  - DNA manufacturing and less frequent administrations

MYO® TECHNOLOGY

RenBio

Acknowledgements

RenBio

Linda Sasset, PhD

Marek Drozdz, PhD

Diego Song, PhD

*Carleigh Sussman

*Luisa Rubinelli

*Andrew Cameron, MS

*Debnath Maji, PhD

*Melanie Walker, PhD

*Andy Thompson

*Robert Miller

*Delcora Campbell, MS, MBA

DARPA

BARDA

BILL & MELINDA GATES foundation

wellcome

NEW YORK STATE OF OPPORTUNITY. Empire State Development

Thank you

RenBio